Specifically, DCs has the key function of initiating T-cell immunity, and DCs can be effectively activated and enhance immunotherapy by tumor-specific antigen (TSA), tumor-associated antigen (TAA), and immune adjuvants (TLR agonists, STING agonists, and C-type lectin receptor (CLR) agonists) 58-61; Co-stimulatory factors OX40 and 4-1BB mRNA can stimulate the proliferation and expansion of CD8+ T cells and enhances T cell-mediated anti-tumor immune responses 62; NK cells also have unique stimulatory receptors (NKG2D and NKp46) to promote NK cells activation and killing of tumor cells 63. The gene discussed is DCLK3; the disease is neoplasm.